Welcome to our dedicated page for REGEN BIOPHARMA news (Ticker: RGBP), a resource for investors and traders seeking the latest updates and insights on REGEN BIOPHARMA stock.
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) is a pioneering biotechnology company based in La Mesa, California, specializing in the development of small molecule therapies for the treatment of cancer and autoimmune disorders. Founded in 2012, the company focuses on innovative immunology and immunotherapy solutions, rapidly advancing novel technologies from pre-clinical stages through Phase I and II clinical trials.
At the core of Regen BioPharma's research is the NR2F6 small molecule activator, which plays a crucial role in immune cell modulation for oncology and autoimmune diseases. The company's pipeline includes mRNA and small molecule therapies aimed at providing groundbreaking treatments for these debilitating conditions.
Regen BioPharma's recent achievements include significant progress in validating its DuraCAR CAR-T cell therapeutic, designed to target CD19 and NR2F6. Initial in vitro experiments have shown promising results, with subsequent studies revealing unexpected outcomes that could pave the way for developing new autoimmune-suppressive T cell therapies. The company has engaged independent Contract Research Organizations (CROs) to verify these findings, ensuring robust and reproducible data.
The company's commitment to advancing its research is further demonstrated by its ongoing efforts in the autoimmune therapeutic category. Regen BioPharma is poised to initiate a Phase I clinical trial, leveraging its deep intellectual property portfolio and novel technologies.
Regen BioPharma's strategy extends to partnerships and collaborations with leading scientific experts and institutions. This approach not only accelerates the development of their therapies but also positions the company as a significant player in the biotech industry.
For more information, visit Regen BioPharma, Inc.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) is set to present at the Emerging Growth Conference on February 22, 2023, from 2:40 to 2:50 PM Eastern Time. This live event will provide a platform for interaction with CEO Dr. David Koos, where shareholder questions will be addressed. Key discussion points include updates on a pending reverse stock split and future financing plans. Registration is available for real-time participation and an archived webcast will also be accessible post-event. The conference showcases companies in growth sectors and aims to connect them with investors.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) invites investors to its live presentation at the Emerging Growth Conference on February 8, 2023. The interactive session will provide insights on the company's strategic plans, drug pipeline, and upcoming 1-for-1500 reverse stock split effective March 6, 2023. CEO Dr. David Koos will address shareholder questions during the event.
Regen BioPharma is focused on advancing therapies for cancer and autoimmune disorders through pre-clinical and Phase I/II clinical trials. The conference presentation is scheduled from 2:20 - 2:50 PM Eastern Time. An archived webcast will be available post-event.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) will present at the Emerging Growth Conference on January 25, 2023, from 3:30 - 3:40 PM Eastern. This online event allows shareholders and the investment community to engage with CEO Dr. David Koos in real time. The company aims to update stakeholders on recent intellectual property and respond to questions during the session. Attendees can register for the event at the [official registration link](https://goto.webcasts.com/starthere.jsp?ei=1575092&tp_key=9111d280ed&sti=rgbp). An archived version of the presentation will also be available on [EmergingGrowth.com](http://EmergingGrowth.com).
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) has filed a provisional patent application focused on using survivin-engineered dendritic cells and exosomes to enhance anti-cancer immunity. This approach aims to improve the immune system's ability to target and destroy survivin-expressing tumor cells while sparing healthy tissue. The company draws on prior work with DCellVax for breast cancer treatment and is positioned to diversify its portfolio in the expanding immunotherapy market, which is projected to reach $100 billion globally. CEO David Koos emphasized the potential for new revenue streams through this innovative strategy.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) announced the addition of Dr. Ravinder Reddy and Dr. Mohammad Haris to its Scientific Advisory Board, enhancing its expertise in immunotherapy. Dr. Reddy, a leading researcher in cancer imaging, has over 200 peer-reviewed publications and numerous awards. Dr. Haris specializes in metabolic imaging technologies for cancer and neurological disorders with over 100 publications. CEO David Koos emphasized the importance of their expertise as the company advances its CAR T-cell and immunotherapy initiatives.
FAQ
What is the current stock price of REGEN BIOPHARMA (RGBP)?
What is the market cap of REGEN BIOPHARMA (RGBP)?
What is Regen BioPharma, Inc.?
What is the NR2F6 small molecule?
Where is Regen BioPharma, Inc. based?
When was Regen BioPharma, Inc. founded?
What are the recent achievements of Regen BioPharma?
What is the focus of Regen BioPharma's current projects?
Who is the CEO of Regen BioPharma, Inc.?
What is the significance of the DuraCAR CAR-T cell therapeutic?
How does Regen BioPharma ensure the validity of its research?
How can I get more information about Regen BioPharma, Inc.?
